GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Price-to-Owner-Earnings

CEL-SCI (CEL-SCI) Price-to-Owner-Earnings : (As of May. 03, 2024)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Price-to-Owner-Earnings?

As of today (2024-05-03), CEL-SCI's share price is $1.63. CEL-SCI does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for CEL-SCI's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of CEL-SCI was 11.72. The lowest was 0.00. And the median was 11.39.


CVM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.985
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-03), CEL-SCI's share price is $1.63. CEL-SCI's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.68. Therefore, CEL-SCI's PE Ratio for today is At Loss.

As of today (2024-05-03), CEL-SCI's share price is $1.63. CEL-SCI's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.68. Therefore, CEL-SCI's PE Ratio without NRI for today is At Loss.


CEL-SCI Price-to-Owner-Earnings Historical Data

The historical data trend for CEL-SCI's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Price-to-Owner-Earnings Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CEL-SCI Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CEL-SCI's Price-to-Owner-Earnings

For the Biotechnology subindustry, CEL-SCI's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Price-to-Owner-Earnings falls into.



CEL-SCI Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

CEL-SCI's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.63/-0.67
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CEL-SCI  (AMEX:CVM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


CEL-SCI Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI (CEL-SCI) Business Description

Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182